Covid-19 divides the biggest medtechs
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Persistence pays off for Kala
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.